A Novel Drug for Borderline Personality Disorder

NCT02097706 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
150
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

The Alfred